KRMC begins monoclonal antibody therapy for COVID-19 treatment
KINGMAN – Kingman Regional Medical Center (KRMC) has begun using monoclonal antibodies to treat high-risk COVID-19 patients. Monoclonal antibodies are proteins made in a laboratory to mimic the body’s natural immune response. With this treatment, a patient receives an intravenous (IV) infusion of the antibodies. This can enhance the patient’s ability to fight the virus that causes COVID-19. In November, The US Food and Drug Administration (FDA) issued an Emergency Use Authorization (EUA) for certain monoclonal antibody therapies. This authorization allows the therapy for COVID-positive patients with high risk for disease progression or hospitalization. Clinical trials suggest that the therapy…